Journal of Pharmacology and Pharmacotherapeutics

REVIEW ARTICLE
Year
: 2020  |  Volume : 11  |  Issue : 4  |  Page : 129--133

Adaptive designs in clinical trials


Sougata Sarkar1, Vartika Srivastava2, Chaitali Patanayak2 
1 Department of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata, West Bengal, India
2 Department of Pharmacology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha, India

Correspondence Address:
Vartika Srivastava
Department of Pharmacology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha
India

The traditional clinical trial is a rigid channel of drug development process. After successful Phase 1 trials and Phase 2 trial with sufficient efficacy and safety, the drugs goes into Phase 3 trials, where it is compared with a placebo or standard treatment (control). Performing this for each new drug separately need more manpower (patients/participant), money (financial resources), and time. On November 2019, the Food and Drug Administration issued a final guidance for the industries entitled, “Adaptive Designs for Clinical Trials of Drugs and Biologics.” They defined adaptive design as “a clinical trial design that allows for prospectively planned modifications to one or more aspects of the design based on accumulating data from subjects in the trial.” In simple words, adaptive design means a design that permits modifications of “the trial procedures and/or statistical procedures of the trial” after its beginning without compromising the validity and the integrity of a trial. There are nine types of adaptive designs that includes adaptive randomization design, group sequential design, sample size re-estimation design, drop-the-losers design, adaptive dose finding design, adaptive treatment-switching design, biomarker-adaptive design, adaptive-hypotheses design, and adaptive seamless Phase II/III designs which has been explained in detail, in this review article. Although the concept of adaptive design has been there from long before but one of the major disadvantages it faces is the lack of uniformity.


How to cite this article:
Sarkar S, Srivastava V, Patanayak C. Adaptive designs in clinical trials.J Pharmacol Pharmacother 2020;11:129-133


How to cite this URL:
Sarkar S, Srivastava V, Patanayak C. Adaptive designs in clinical trials. J Pharmacol Pharmacother [serial online] 2020 [cited 2021 Jun 13 ];11:129-133
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2020;volume=11;issue=4;spage=129;epage=133;aulast=Sarkar;type=0